LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC director Barry James Christopher reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs vested and were exercised into ordinary shares. Of these, 486 shares were withheld to cover tax liabilities, leaving him with 7,918 ordinary shares held directly after the tax-withholding disposition and 8,404 ordinary shares following all transactions. He also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC Chief Innovation Officer Ahmet Tezel reported routine equity compensation activity. On June 15, 2026, 2,965 restricted stock units vested and were settled in ordinary shares under the company’s incentive plan. To cover tax liability, 1,032 of these shares were withheld, a non-market disposition.
After these transactions, Tezel directly holds 6,090 ordinary shares and 5,931 unvested restricted stock units that remain subject to future vesting and forfeiture conditions. The filing reflects compensation-related equity vesting rather than open-market buying or selling.
Nygaard-Andersen Jette reported acquisition or exercise transactions in this Form 4 filing.
LivaNova PLC director Jette Nygaard-Andersen received a grant of 2,383 Restricted Stock Units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one ordinary share of the company under the 2025 Director Incentive Award Plan and its award agreement.
The RSUs vest on June 15, 2027, subject to continued service through the vesting period and compliance with the plan terms. Following this grant, Nygaard-Andersen holds 2,383 RSUs directly, all tied to future delivery of ordinary shares if vesting conditions are met.
LivaNova PLC director William A. Kozy reported equity compensation-related transactions involving ordinary shares and restricted stock units. On June 15, 2026, previously vested RSUs were settled into 5,681 ordinary shares, and 682 of those shares were withheld to satisfy tax liability, leaving him with 37,566 ordinary shares held directly.
Kozy also received a new grant of 2,383 restricted stock units under the company’s 2025 Director Incentive Award Plan. These RSUs each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service and the plan’s terms.
LivaNova PLC director Stacy Enxing Seng reported routine equity compensation activity. On June 15, 2026, vested restricted stock units were settled into 4,042 ordinary shares, classified as an option/RSU exercise. To cover related taxes, 486 ordinary shares were withheld at $79.70 per share rather than sold on the open market.
Following these transactions, she directly holds 15,307 ordinary shares. Enxing Seng also received a new grant of 2,383 restricted stock units under LivaNova’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service and plan terms.
LivaNova PLC director Story Brooke reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On June 15, 2026, 4,042 RSUs vested and were exercised into ordinary shares, and 486 of those shares were withheld to satisfy tax liabilities at a price of $79.70 per share.
Following these transactions, Brooke directly holds 9,788 ordinary shares. On the same date, Brooke also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC director Donald Zurbay reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, vested RSUs were settled into 2,560 ordinary shares under the company’s 2025 Director Incentive Award Plan. To cover tax obligations, 308 ordinary shares were withheld at $79.70 per share, leaving Zurbay with 2,252 ordinary shares directly held after the transactions. He also received a new grant of 2,383 RSUs that each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC reported a Form 144 notice showing a reported sale of 1,800 shares of Common Stock by Francesco Bianchi on 05/26/2026 for $136,350. The filing also lists restricted stock unit vesting events of 708 shares on 06/15/2024 and 492 shares on 06/29/2021, both noted as granted under the issuer's equity compensation plan. The excerpt includes a Common Stock figure of 54,933,538 with date 06/15/2026.
LivaNova PLC director Jette Nygaard-Andersen filed an initial Form 3 reporting her ownership in the company’s common stock. The filing shows she beneficially owns 0 shares of Common Stock directly following this reporting, and it does not report any purchase or sale transactions.
LivaNova PLC reported the results of its 2026 Annual General Meeting, where shareholders approved all 10 proposals presented. Eleven directors were re-elected for terms running until the 2027 AGM, maintaining continuity on the board.
Shareholders gave advisory approval to the U.S. say-on-pay vote for named executive officers and to the UK directors’ remuneration report. They also ratified PricewaterhouseCoopers LLP as both the U.S. independent registered public accounting firm and the UK statutory auditor for 2026 and authorized the board or Audit and Compliance Committee to set the UK auditor’s fees.
Investors renewed authority for directors to allot shares up to a nominal £10,985,296 and to disapply pre-emption rights on the same nominal amount. They also approved share repurchase contracts allowing buybacks of up to 10% of total issued ordinary shares as of April 13, 2026.